Which companies are Mochida Pharmaceutical's closest peers?

The cockpit's peer set: Nuvectis Pharma (NVCT), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Earth (4985.T), Jenkem Technology (688356.SS), Shandong Wit Dyne Health (000915.SZ), Hunan Fangsheng Pharmaceutical (603998.SS), Zevra Therapeutics (ZVRA), Center Laboratories (4123.TWO).

Is Mochida Pharmaceutical expensive compared with its peers?

On forward p/e it trades at 15.2× against a peer median of 17.7×, 5th cheapest of 10 in its peer set.

How has Mochida Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned -5.9% against -5.8% for the median peer; over one year +3.6%.

← CockpitCompetitor Analysis › 4534.T Mochida Pharmaceutical Co., Ltd.Open in the cockpit ↗

Mochida Pharmaceutical Co., Ltd.4534.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Momentum neutral 53

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$683M

US dollars, full cap

Free float

51%

of shares outstanding

$/day

$969,887

20-day average traded

Fwd P/E

15.2×

forward earnings

ROIC−WACC

+1.3 pp

WACC 5.0%

Hurdle

n/a

no reverse DCF

Next earnings

3 days

9 Nov 2026

Close · JPY¥3,165

1D-6.8%

1W-2.3%

1M+1.1%

3M-0.5%

6M-5.9%

YTD-10.5%

1Y+3.6%

ATR %2.4%

52w lowhigh20.2% off high

What Mochida Pharmaceutical does

Employees: 1,479

Mochida Pharmaceutical at a glance

Size Mochida Pharmaceutical (4534.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $683M, the 913th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,165 on 6 Nov 2026.

Performance Over six months the shares fell 5.9%, against -5.8% for the median peer and +1.8% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 14.7% over the last twelve months (peer median +17.0%); the operating margin is 9.1% (peer median 11.5%).

Valuation It trades at 15.2× forward earnings against a peer median of 17.7× (5th cheapest of 10).

Capital Return on invested capital runs 1.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Mochida Pharmaceutical against the median of its 20 peers (local-currency closes).

Mochida Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	¥122B	¥117B	¥105B	¥103B	¥103B
Revenue growth	—	+11%	+2%	0%	—
Gross profit	¥57.3B	¥56.3B	¥53.8B	¥52.1B	¥55.1B
EBITDA	¥14.2B	¥13.1B	¥11.1B	¥8.61B	¥11.2B
Net income	¥9.19B	¥7.90B	¥5.68B	¥4.55B	¥6.65B
Free cash flow	n/a	-¥10.0B	¥7.19B	-¥9.78B	¥5.13B
Capital expenditure	n/a	¥2.69B	¥2.16B	¥2.30B	¥2.17B
Total debt	¥10.8B	¥10.3B	¥342M	¥369M	¥190M

Quarterly statements and history in the cockpit →

Mochida Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Mochida Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mochida Pharmaceutical is the large dot.

Mochida Pharmaceutical competitors and peer comparison

How Mochida Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mochida Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure	4534.T	Peer median	Rank in peer set
1-month return	+1.1%	-5.6%	7th highest of 21
6-month return	-5.9%	-5.8%	11th highest of 21
Distance from 52-week high	-20.2%	-29.1%	6th highest of 21
Revenue growth (TTM)	+14.7%	+17.0%	9th highest of 17
Operating margin	9.1%	11.5%	7th lowest of 16
Forward P/E	15.2×	17.7×	5th cheapest of 10
ROIC minus cost of capital	+1.3 pp	-3.3 pp	5th highest of 14
EV / EBITDA	6.4×	12.7×	3rd cheapest of 9
Net debt / EBITDA	-1.2×	-0.9×	4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Mochida Pharmaceutical 4534.T	Japan	$683M	-6%	+15%	9%	15.2×	n/a	n/a
Nuvectis Pharma NVCT	United States	$683M	+79%	n/a	n/a	n/a	n/a	n/a
Hubei Biocause Heilen Pharmaceutical 301211.SZ	China	$682M	-5%	+13%	4%	n/a	n/a	n/a
Earth 4985.T	Japan	$682M	+6%	+6%	4%	17.7×	-2.5%	-1.8%
Jenkem Technology 688356.SS	China	$686M	-23%	+52%	11%	36.8×	41.4%	+11.2%
Shandong Wit Dyne Health 000915.SZ	China	$687M	-33%	-36%	36%	9.1×	n/a	n/a
Hunan Fangsheng Pharmaceutical 603998.SS	China	$678M	-6%	+10%	19%	12.7×	-2.4%	+6.4%
Zevra Therapeutics ZVRA	United States	$690M	+4%	+75%	31%	11.8×	0.0%	+51.6%
Center Laboratories 4123.TWO	Taiwan	$676M	-28%	+4%	5%	n/a	50.8%	+16.2%
Achieve Life Sciences ACHV	United States	$692M	+29%	n/a	n/a	n/a	n/a	n/a
Beijing Beilu Pharmaceutical 300016.SZ	China	$692M	-16%	+23%	11%	88.2×	10.3%	+7.9%
Sagimet Biosciences SGMT	United States	$693M	+28%	n/a	n/a	n/a	n/a	n/a
Philogen PHIL.MI	Italy	$694M	-7%	+295%	79%	32.5×	n/a	n/a
FDC FDC.NS	India	$672M	+4%	+10%	14%	n/a	25.9%	+10.3%
Bliss GVS Pharma BLISSGVS.NS	India	$698M	+126%	+21%	15%	n/a	37.0%	+10.1%
Immix Biopharma IMMX	United States	$668M	-17%	n/a	n/a	n/a	n/a	n/a
Zhejiang Wecome Pharmaceutical 300878.SZ	China	$666M	+10%	+40%	-65%	n/a	n/a	n/a
Sun Pharma Advanced Research SPARC.NS	India	$665M	+16%	+3,141%	84%	n/a	n/a	n/a
Luoxin Pharmaceuticals Group Stock 002793.SZ	China	$664M	-26%	-10%	-9%	n/a	0.3%	-17.9%
Lepu Biopharma 2157.HK	Hong Kong	$663M	-45%	+47%	7%	61.2×	n/a	n/a
HeiLongJiang ZBD Pharmaceutical 603567.SS	China	$705M	-29%	-82%	n/a	6.3×	10.5%	-25.1%

Questions

Which companies are Mochida Pharmaceutical's closest peers?: The cockpit's peer set: Nuvectis Pharma (NVCT), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Earth (4985.T), Jenkem Technology (688356.SS), Shandong Wit Dyne Health (000915.SZ), Hunan Fangsheng Pharmaceutical (603998.SS), Zevra Therapeutics (ZVRA), Center Laboratories (4123.TWO).
Is Mochida Pharmaceutical expensive compared with its peers?: On forward p/e it trades at 15.2× against a peer median of 17.7×, 5th cheapest of 10 in its peer set.
How has Mochida Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned -5.9% against -5.8% for the median peer; over one year +3.6%.